Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.

Item

http://www.wikidata.org/entity/Q35179843

Q35179843

about

Cardiovascular safety of anti-diabetic drugs The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials Sodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metformin Patient considerations in type 2 diabetes - role of combination dapagliflozin-metformin XR Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects Update on the treatment of type 2 diabetes mellitus Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review New and emerging drugs and targets for type 2 diabetes: reviewing the evidence Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis The Efficacy and Safety of Chinese Herbal Medicine Jinlida as Add-On Medication in Type 2 Diabetes Patients Ineffectively Managed by Metformin Monotherapy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Sodium-glucose transporter-2 (SGLT2; SLC5A2) enhances cellular uptake of aminoglycosides.The role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment.Can you trust your animal study data?Sodium-Glucose linked transporter 2 (SGLT2) inhibitors--fighting diabetes from a new perspective.Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK.Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data.Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus.Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial.SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.Update on developments with SGLT2 inhibitors in the management of type 2 diabetes Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention.Dapagliflozin for the treatment of type 2 diabetes.The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.

P2860

Q26741082-34C6F0FF-27F5-4F07-8944-0D648B751363 Q26748870-1C56FEB0-69D7-43E3-9357-CFBE8166BC1C Q26752815-FFD30477-D5B7-4214-AF04-7E9D0D5DD2A8 Q26766404-10006FA6-CD8A-458C-B5FE-5172DACC17ED Q26782225-E4974FBB-88BF-470B-8E41-CFD79104B74F Q26824616-1078A6A8-6DC2-4FBA-8327-518A9FCEFF27 Q26851797-E24059A1-BC98-4BE2-B5C0-A86D4318D3D5 Q26864336-365E213B-3836-4ED5-9407-0AEA8C655A80 Q27027105-5FDA3E2A-7710-46A9-9940-0AA644FCB4C6 Q28072352-2D9A322A-A765-4CB9-BF85-0042541A81DD Q28072765-0F8B855F-724A-48FB-BAFD-09827788D58E Q28073342-E121E3D4-2F9C-4567-8C48-A683907EF7D5 Q28074843-C00E1B19-3A17-40E2-9E5D-EC23E7481D58 Q28079134-D51051A7-B1A0-41CC-AB97-92A53D70DFB8 Q28085516-F2ECFCAC-C362-4BD6-906E-3983321B32A5 Q28546797-D9C692D4-5FD0-4759-A86F-D385EC0A418B Q28548552-0062FB05-456D-44AF-A521-A2807CAE56F4 Q28553482-8347589B-F381-4DBB-80B2-60D444E07FC1 Q30249371-47F24DBA-5889-4095-8157-6FFAE5CADD69 Q30429061-4FD80609-B970-4E4D-9266-C21118D15BD1 Q30663494-C5A9C0B2-946D-4E84-84DC-72F9DC3B3746 Q30829341-0330DE33-D8FF-4A00-A591-A76A7A7064BE Q30833760-7D07E15B-0149-4418-90B9-582C1FA3306D Q30863970-BC271705-DC74-4165-9A34-A2C72C3171B2 Q30877953-87AC8410-7F3B-4333-91BA-2FB9A8D29B39 Q30903369-875B9627-7840-45F8-9E85-0FF7B750E789 Q32186373-42173B73-2FA6-47A1-AE14-F4CCA394E622 Q33166813-0E2A060D-34E9-4F4C-9979-1FF665F9A9B2 Q33785128-CAD7876D-31E5-49E3-BA7B-2A92D5F48053 Q33785136-17ED294F-0DF1-43BC-9365-295782AB4A10 Q33859212-5039D906-EB50-478F-8B29-F5D0D148CEC3 Q33859245-C51AF910-E492-4881-8E1B-E02FD1A2AB44 Q33871321-8F19FBF9-6A41-49F7-9C39-585210016286 Q33882438-831FA950-2F9C-489F-A6EF-FE737135659D Q33885732-EF4A1642-1C99-421F-AA00-8912E0923569 Q34161881-54F93EB3-D005-4FDF-B482-A30353EB2AC2 Q34198692-01C2E7CA-15A1-4AA5-977B-AA869CD9EBBB Q34201551-9737BBF9-C823-487F-824D-A19F781C1CD4 Q34262543-CB7AA85B-B011-441E-A4B3-4ABE2828CFF0 Q34315521-0E1AE2BE-3183-4B48-B18B-8F6EB1EB8096

P2860

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.

Item

http://www.wikidata.org/entity/Q35179843

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu